NANOVIRICIDES, INC.

NanoViricides, Inc. has entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC. This agreement enables the company to offer and sell shares of its common stock from time to time through an "at the market" offering. The Sales Agent will earn a 2.0% commission on the gross proceeds from these sales. A prospectus supplement was filed in connection with this agreement under the company's existing shelf registration statement.

NanoViricides, Inc. participated in the Alliance Global Partners Healthcare Companies Showcase, where Dr. Anil R. Diwan discussed the company's drug candidates for the Ebolavirus epidemic in the Democratic Republic of Congo (DRC). He highlighted NV-387, a broad-spectrum antiviral entering Phase II trials for Mpox in DRC, and NV-387 encapsulating Remdesivir as a backup. Both candidates are expected to be effective against the current Bundibugyo strain of Ebolavirus. The company also noted its existing clinical site in DRC for Mpox patients.

NanoViricides, Inc. completed a registered direct offering, raising approximately $2.0 million in gross proceeds. The offering included 1,333,334 units, each consisting of common stock (or pre-funded warrants) and accompanying common warrants. The net proceeds are intended for working capital, R&D, clinical trials, and strategic acquisitions.

NanoViricides, Inc. reported a reduced net loss of $6.0 million for the nine months ended March 31, 2026, compared to $7.4 million in the prior year. The company significantly increased its cash and cash equivalents to $3.2 million, primarily through financing activities including a $5.4 million Registered Direct Offering and $1.9 million from ATM sales. Despite these capital raises, management expressed substantial doubt about the company's ability to continue as a going concern for at least the next 12 months due to anticipated continued losses and no foreseeable revenues. The company is progressing with its NV-387 antiviral drug, anticipating the Phase Ia/Ib clinical study report submission and planning for Phase II trials for MPox.